5:27 PM
 | 
Apr 01, 2008
 |  BC Extra  |  Company News

Progenics up after Canada approves Relistor

Progenics (NASDAQ:PGNX) gained $1.14 (17%) to $7.67 on Tuesday after Health Canada approved subcutaneous Relistor methylnaltrexone...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >